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1. Introduction
The high frequency of cases of hepatocellular carcinoma (HCC) led to vigorous efforts to
identify the biological behavior and the pathogenetic mechanisms of this disease. The esti‐
mated 564.000 new cases worldwide and almost the same number of deaths in 2000 make it
necessary to understand how to treat and control HCC [1]. This is possible acquiring a deep
knowledge of the natural history of the disease, particularly of its initial steps which bring the
parenchyma to the first changes and expose the cells to chronic insults, leading to a long
standing disease endowed with a high risk of cancer development.
The pathogenesis of HCC is a complex phenomenon-, given the high number of variables and
factors involved in liver function and of the possible pathway activation or deregulation during
liver disease.
The first valuable step is based upon the death of hepatocytes: different pathological conditions
able to induce hepatocyte damage and death will determine recruitment of inflammatory cells
and deposition of connective tissue.
On the one hand this fact shows the relatively limited range of liver parenchyma response to
various kind of damage. The structure and function of the organ are associated with necroin‐
flammatory, fibrotic and cholestatic changes as the main phenomena which the parenchyma
response to damage is able to produce.
On the other hand, this kind of elementary lesions is mostly self-maintaining: in fact, some of
the main consequences of hepatocyte destruction and fibrotic parenchymal substitution are
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the changes in blood flow and in the composition and function of both extracellular matrix
and microenvironment of the liver [1], which heavily influence hepatocyte life and function.
There is a strict connection between different phenomena concerning the liver in normal and
pathological conditions. Chronic inflammation and fibrosis are well known as the main
changes leading to neoplasia harboring in the majority of chronic liver diseases; but some
insights into the mechanisms and the cellular types which can act either in organ development,
or in regenerative and neoplastic processes represent one of the objective of this text. At this
regard, a particular role in the relationship between microenvironment and liver cells prolif‐
eration concerns tumor associated fibroblasts (TAFs), considered critical for tumor growth and
progression.
Experimental studies in solid tumors other than HCC suggest a possible origin of these cells
from mesenchymal stem cells derived from the bone marrow, but in vitro human models lack.
These cells exert important functions in cirrhotic and neoplastic liver parenchyma: recently it
has been demonstrated the presence in human neoplastic livers of a population of multipotent
adult stem cells with properties of tumor associated fibroblasts, while a population of MASCs
derived TAFs is already present in cirrhotic, not yet neoplastic parenchyma. Furthermore,
mesenchymal stem cells isolated from non-neoplastic and non-cirrhotic livers can acquire a
TAF phenotype when grown in a medium conditioned by tumor cell lines [2]
After a brief evaluation of the main factors playing important roles in the pathogenesis and
progression of hepatocellular carcinoma (pathways deregulation with respect to morpholog‐
ical changes, molecular factors and pathways cross-talk influencing interplay between
different cellular elements, role of extracellular matrix and angiogenesis), the relationship
between liver embryogenesis, regeneration and neoplastic growths is considered, inparticular
as far as the interplay between parenchymal cells and stromal component in non-neoplastic
and neoplastic liver is concerned. Further deeper look is addressed to more recent progresses,
which can really offer new important insights in the pathogenesis and treatment of hepato‐
cellular carcinoma: microRNA deregulation and tumor associated fibroblasts. The former
show a great potential in targeting a lot of genes involved in the neoplastic process: different
tumors in different organs show strict relationships with the effects of groups of miRNA
similarly associated for some organs, giving rise to signatures characteristic of neoplastic
development, able to predict prognosis and to represent targets for new therapeutic chances.
Similar results come from the action of miRNA in hepatocellular carcinoma, where distinct
tumor subtypes are associated with different miRNA signature.
Tumor associated fibroblasts represent a population of stromal cells able to influence in crucial
ways the parenchymal microenvironment changes which accompany all steps of HCC
development, from the origin to progression and diffusion.
1.1. Growth factors and molecular pathways
With the ongoing of the pathological process the proliferation of liver cells accelerates and
monoclonal populations occur: this is the hallmark of all preneoplastic lesions and takes places
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also in HCC. From this point of view the foci of phenotypically altered hepatocytes represent
the first discrete step, morphologically identifiable, in the way leading to cancer.
The foci of altered hepatocytes contain differentiated hepatocytes that have acquired molecular
aberrations and changed their metabolic properties [3]: this may allow the progress to
malignant phenotype. These cells and their morphological and biochemical phenotype are
unstable and, given the absence of uniformity in foci, the clonal origin is partly suggested: at
least 8 cytomorphological and cytochemical atypical foci types exist [3]. These premalignant
changes represent perhaps one of the first effects of viral or environmental damage.
The main etiological agents of HCC are well known: HBV,HCV and Aflatoxin B1 are consid‐
ered causative agents of about 80% of cases [1]. During last years a lot of genomic aberrations
have been identified and the mechanisms of interaction at molecular level between liver cells
and etiologic agents in producing gene changes responsible of the development of neoplasia
have been studied and often understood [1].
After the production of foci of altered hepatocytes, the subsequent step, morphologically
defined, is represented by the formation of dysplastic foci and dysplastic nodules: in these
lesions, probably, molecular changes can take further development with a selection of genetic
and epigenetic changes leading to a proliferative advantage for altered hepatocytes and to the
involvement of several regulatory pathways in simultaneous disorders favoring the passage
from dysplastic to neoplastic lesion.
The simple increase in cell proliferation and DNA synthesis associated with increasing
enzymatic and metabolic changes is not enough to give rise to carcinogenesis.
The production of growth factors and hormones (e.g. Insulin, IGF2, TGF alfa, TGF beta, HGF,
Transferrin, VEGF), of cytokines and chemokines and the activation or deregulation of
different pathways give an essential contribution to the development of neoplasia, but the
whole mechanism of the transformation from dysplastic to fully neoplastic lesion is not yet
completely understood.
A crucial element to consider in this context comes from the interaction between the different
cell types present in liver parenchyma.
For example, hepatocyte proliferation is regulated by cytokines (especially IL-6) produced by
Kupffer cells as well as by endothelial cells and hepatic stellate cells. On the other hand,
hepatocytes modulate sinusoidal endothelium phenotype and its production of prostaglan‐
dins, endothelin, IL-1 e IL-6 and Hepatocyte Growth Factor [4]. Moreover, the complexity of
cross talk between cellular types is relevant in the relationship between hepatocytes and
hepatic stellate cells: the production of peptides stimulating hepatic stellate cells proliferation
leads to the increased production of cytokines by hepatic stellate cells. These latter are able
either to inhibit or to stimulate hepatocyte proliferation [5]. For example, TGF-beta produced
by hepatic stellate cells can act as an inhibitor of liver cells replication; moreover, IL-6 response
is downregulated by SOCS-3 (suppressor of cytokine signaling 3) with blocking of JAK
mediated STAT-3 activation [4, 5].
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Regarding the interaction between hepatocytes and Kupffer cells, growth factors and cytokines
activate critical transcription factors, such as AP-1, NFkB, STAT-3, inducing Kupffer cells
activation and production of IL-6 thus increasing liver cell DNA synthesis [5].
1.2. Extracellular matrix
The site where the described interactions take place is not a silent structure away from any
biochemical activity: the relationship between hepatocytes and extracellular matrix is partic‐
ularly active and crucial [3].
A lot of adhesion molecules and receptor mediating cell-matrix binding are present.
Extracellular matrix acts as a reservoir and presenter of cell growth factors and cytokines; it
undergoes a rapid turnover and significant modifications, often induced by liver parenchymal
and non-parenchymal cells, through the production of matrix-degrading enzymes, such as
metalloproteinases, and their inhibitors which control the extracellular matrix degradation.
Soluble mediators able to influence hepatic stellate cells and Kupffer cells induce the produc‐
tion of proteinases which may initiate the process of matrix degradation. Kupffer cells adhesion
on endothelial cells via CD4 and ICAM-1 produce hepatic stellate cells stimulating factors:
again, hepatic stellate cells, modulated by hepatocytes, endothelial cells, Kupffer cells, platelets
and inflammatory cells play a role in fibrogenesis and liver morphogenesis.
When extracellular matrix at sinusoidal subendothelial level undergoes some kind of disrup‐
tion, hepatocytes can lose their differentiated function and morphofunctional changes take
place: altered porosity in sinusoidal barrier and impaired movement of solutes and macro‐
molecules into and out of Disse spaces favor fibrogenetic progression, with further functional
impairment. In particular, extracellular matrix turnover and degradation are under the control
of different factors, either at extracellular (metalloproteinases) or intracellular level (lysoso‐
malcathepsins) [3].
Collagenases acting on fibrillar collagen, stromelysins (degrading collagen IV, gelatin, laminin,
fibronectin), gelatinase, neutrophilic collagenase ( acting on collagen I and III) and so on
parallel the activity of molecules expressed by hepatocytes and hepatic stellate cells, function‐
ing as inhibitors of metalloproteinases (tissue inhibitors of metalloproteinases 1 and 2 and alfa
2 macroglobulin), with a regulation of relative gene expression by same cytokines and growth
factors as metalloproteinases [3].
Interstitial collagenase activity is increased in liver fibrosis, mainly during the early develop‐
ment of extensive lesions, but diminishes with advanced cirrhosis.
1.3. Angiogenesis
Fibrogenetic progression with Disse spaces fibrosis and sinusoidal capillarization induces
great impairment particularly in hepatocellular secretion of proteins (albumin, clotting factors,
lipoproteins), associated with dramatic changes in fluid dynamics [3].
Genetic changes and local hypoxia may lead to secretion of soluble angiogenic factors, with a
complex interplay between cells, basal membranes and pro-or antiangiogenic factors.
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The proangiogenetic factors exert their influence in particular by activating endothelial cells,
which, when activated, loose interendothelial cells contacts and breakdown the surrounding
basement membrane and extracellular matrix: the associated phenomena of proliferation and
migration of endothelial cells are widened by further secretion of angiogenic factors,former‐
lysequestered in perivascular extracellular matrix. The secretion of protease induces the release
of free vascular endothelial growth factor which stimulates endothelial cells [6, 7].
Endothelial  cells  proliferation and migration is  followed by the tendency to assemble in
tubular  structures,  with  subsequent  basement  membrane  material  production  and  peri‐
cytes (supportive vascular smooth muscle cells) recruitment through the action of PDGF
beta:  these  newly  formed  vascular  channels  nevertheless  show  irregular  and  variable
diameter, with abnormal branching pattern, incomplete structure of basement membrane
and only partialpericytes cover, which represent the main characteristics of new vascular
channels  associated  with  the  development  of  neoplastic  growth  at  the  beginning.  The
process go on when phenomena ofhypoxia in the central area of the tumoror some viral
component if  present ( for example HBX protein ) stimulate the production of Hipoxia
Inducible Factor-1alfa, followed by the action of VEGF glycoproteins (A,B,C,D and placental
growth factor) on corresponding receptors (flt1 and flk1) on endothelial cells. It has been
demonstrated that Trans arterial chemoembolization (TACE) for hepatocellular carcinoma
treatment  is  followed by  parallel  increase  of  VEGF expression  related  to  microvascular
density and hypoxia [6,  7],  which confirms the relationship between ischemia and reac‐
tive neoangiogenesis.
Angiogenic stimuli produce different effects in normal, cirrhotic and neoplastic liver paren‐
chyma:within normal and regenerating tissue new functional sinusoids appear, while in
chronic liver disease capillarized vascular structures take place [7].
The high number of complex interplays, here rapidly summarized, underlines the crucial
connection between parenchymal cells, non-parenchymal cells and extracellular matrix,
including vascular component. Again this phenomenon-show significantsimilarities between
different physiological and pathological events involving the liver.
2. Liver development, regeneration, neoplasia: The role of stem cells
It has been recognized the existence, in the liver, of a strict connection between development,
regeneration, and carcinogenesis [8, 9]. As a consequence, researchers are trying to dissect the
molecular mechanisms regulating liver homeostasis, the comprehension of which could open
the way to new targeted therapies for liver regeneration, liver cirrhosis and primary liver
cancers [8, 9].
Liver development involves complex mechanisms. Multipotent tissue specific progenitor cells,
derived from blastocyst inner cell mass stem cells, give rise to the different organs [8].
Specifically, fibroblast growth factor (FGF) from the cardiac mesoderm, through a coordination
of signaling with bone morphogenic proteins from the septum transversum mesenchyme,
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influences the hepatic induction [10-14]. In fact, committed foregut endoderm elements,
through WNT signaling, promote liver bud emergence [15-17]: hepatoblasts invade the septum
transversum mesenchyme to give rise to liver bud and proliferate under the influence of
mesenchymal cells derived cytokines and growth factors, such as FGF, HGF and TGF beta
[18-21] and of neighboring endothelial cells signaling.
The hepatoblasts show bipotential characteristic and specific pathways induce their differen‐
tiation into hepatocytes or biliary epithelium, respectively. Some studies suggest the ductal
plate as the site of fetal liver progenitor cells, with 4 hypothetical anatomic compartments [22]:
hepatocytes which meet the canal of Hering, pankeratin positive cells in the canal of Hering,
intraductalcholagiocytes, peribiliary“ null” cells.
After injury, liver regeneration processes are strictly related to the extent of the loss of liver
parenchyma [8] Specifically, after experimental partial hepatectomy, mass restoration is
mainly due to mitotic division of mature liver cells [23], while when this regenerative capacity
is overwhelmed by massive parenchymal loss, for example in chronic liver disease, mass
regeneration implies the activation of a liver progenitor cell compartment [22]. The molecular
pathways activated in this latter case suggest a recapitulation of the fetal development [8]. In
fact progenitor cells phenotypes and antigenic profiling are similar to fetal liver: these cells are
located at the canal of Hering; the presence of label retaining cells within the iuxta portal,
proximal biliary tree (slow cycling cells which retain Bromodeoxyuridin (BRDU) label for 8
weeks after experimental injury related cell division) confirm this site as a possible stem cell
niche [22]. Similar observations concern peribiliary hepatocytes, mostly identified as BRDU
positive very early in post-injury period, at variance with mid-acinar and central acinar
hepatocytes, involved in rapid turnover for regenerative response to the loss of parenchyma.
On the other hand, intraductalcholangiocytes and peribiliary “null” cells are less likely to take
a role in the niche population, due also to the difficult evaluation of their relationship with
neighbor liver parenchyma [22].
Liver  regeneration  takes  places  within  some  days  or  few  weeks  from  the  insult.  After
experimental  partial  hepatectomy,  inflammatory  cells  produce  TNF-alfa  which  damages
surviving cells, but induces DNA synthesis and adult liver cells proliferation; this mecha‐
nism  needs  the  presence  of  a  specific  receptor  on  hepatocytes  (Tumor  necrosis  factor
Receptor  1).  TNFR1-null  mice  can  nevertheless  grow  to  adulthood,  demonstrating  the
possible development also in the absence of this interaction TNF alfa-TNFR1. This is simply
one out of several mechanisms (such as the action of drugs or hormones) which increase
hepatocyte proliferation, while interaction with TNF is not a unique way for liver develop‐
ment [24]: although TNF production and Glutation (GSH) synthesis represent rapid reaction
to experimental  hepatectomy, TNF simply activates different factors (such as NFKB and
SEK-1,  a  stress  related  kinase)  that  permit  hepatocytes  to  survive  to  TNF  exposure.
“Surviving hepatocytes are then surveyed for damage and repaired or deleted” [24]: this is
a  defensive,  initial  mechanism that,  together  with  antiapoptotic  and antioxidant  factors,
makepossible subsequent parenchymal regeneration. All these observations show a complex
picture of stress regulated intracellular signals that allow adult hepatocytes to proliferate,
to survive without proliferation or to dye.
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Chronic inflammatory response, growth factors and DNA damaging agents (including ROS)
also play a role [25, 26], favoring the involvement of progenitor cells in regenerative / prolif‐
erative activity and therefore probably also favoring tumor development.
Type and duration of exposure to ROS, increasing after cellular stress, play a pivotal role in
choosing the direction of cells destiny. An acute and transient increase in ROS is necessary for
proto-oncogenes and growth factors to induce cellular proliferation [24]. Interestingly,
similarly toregenerative response, with H-RAS mediated proliferative activity, malignant
transformation also requires K-RAS proto-oncogene activation, inducing ERK 1-2 activation
[24]. Surviving hepatocytes surveillance could therefore be overwhelmed by stress induced
proliferative stimuli associated to malignant transformation.
On the one hand, normal livers, which undergone experimental hepatectomy, show a regen‐
erative, mitotic response starting from adult hepatocytes. On the other hand, in the presence
of a chronic parenchymal damage, the response isbased upon progenitor cells, with molecular
signaling patterns that suggest a recapitulation of fetal development [8].
A part from experimental parenchymal damage, chronic ethanol consumption generally
increases the death rate of mature hepatocytes. This stimulates a compensatory regenerative
response to preserve normal liver mass and function. Nevertheless, most of the mature
hepatocytes that survive in alcohol damaged livers are replicatively senescent and hence
incapable of proliferating to replace their dead neighbors, given the chronic alcohol exposure
which inhibits the induction of DNA synthesis. Hence, regeneration of alcohol damaged livers
involves the expansion and differentiation of facultative liver progenitor cells [24]. This
regenerative mechanism requires lengthening the time needed for liver mass reconstitution,
due to the time necessary for differentiation of progenitor cells.
On the whole, the reparative processes take advantage of two principal strategies of defense,
depending on the extent of the damage [8]. While mild injury is mainly repaired through
compensatory hyperplasia of hepatocytes, severe damage implies the activation of a liver
progenitor cell compartment [27]. In both cases, other non-parenchymal cells (stellate cells,
vascular and biliary cells) proliferate as soon as hepatocytes starts to [27]and cooperate to
restore morphofunctional competent liver tissue. In rodent experimental models with chronic
liver injury.
HGF and EGF promote the upregulation of proliferation rate and expansion of oval cells, while
TGF-beta exerts the opposite effect on oval cells [28-31], with an upregulation of the WNT-Beta
Catenin pathway in acute and chronic liver injury experimental models [8]. These data again
suggest symmetry between fetal development and regenerative mechanisms. Molecular
mechanisms involved in fetal development, when identified, can allow to target pathways
connected with parenchymal damage: tyrosine kinase inhibitors, for instance, are able to
inhibit progenitor cell response, liver fibrosis and liver cancer development in a mouse model
of chronic liver injury [32]; C-kit inhibition by imatinibmesylate attenuates progenitor cell
expansion and inhibits liver tumor formation in mice [32].
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Therefore, the presence of pathways playing a role either in fetal development or in regener‐
ative but also in neoplastic phenomena opens important perspectives: three distinct cell
lineages can be found in the liver,susceptible of neoplastic transformation: mature hepatocytes,
small proliferating hepatocytes and stem cells [33, 34].
Specifically, hepatocellular carcinoma might result from dedifferentiation of mature hepato‐
cytes, from activation of oval cells, from arrested differentiation of tissue based stem cells, the
latter being an expression of blocked ontogeny, linked to hepatocarcinogenesis. Evidence of
the fact that hepatocarcinogenesis partly recapitulates fetal development comes from some
observations: both progenitor and fetal cells are self-renewing, with heterogeneous progeny
and limitless division; bipotent cells, with hepatocytic and cholangiocytic potential are present
in fetal livers and have been isolated in a number of HCC cell lines; finally, the strict relation‐
ship between tumor cells and fetal program is testified by the fact that HCC cell lines (e.g.
Huh1, Huh 7, Hep 3b cell lines) share with fetal liver progenitors several oncofetal markers
and that HCC characterized by a gene expression profile similar to fetal hepatoblasts have a
poorer prognosis than HCC with an adult-type genomic profile [35-39].
According to the possible origin from progenitor cells or from dedifferentiated adult cells,
HCC could assume different phenotypes and be linked to the activation of different pathways,
associated to variable parenchymal morphological changes. For instance, significantly fewer
HCCs expressing CK7 or CK19 show nuclear beta Catenin expression. The beta catenin
pathway could preferentially involve “mature“ hepatocytes versus less “mature“ (progenitor)
phenotype cells, with CK7 and CK19 expression,associated withless advanced fibrosis in non-
tumoral parenchyma [40].
CK19 expression in HCC can change with different expression of beta catenin: decreased
fibrosis degree in the non-tumoral parenchyma parallels reduced nuclear beta catenin
expression [25].
Regarding oval cells, many of the compounds that induce their proliferation are DNA-
damaging agents or carcinogens, therefore oval cells can be considered as potential precan‐
cerous cells [41]. Oval cells activation with “ductular reaction“ represent the expansion of a
transit amplifyingcell compartment of small biliary bipotent cells [25].
In cirrhosis, hepatocytes are characterized by senescence determined by telomere shortening,
while mesenchymal cells (e.g. endothelial cells and stellate cells) seem not to be affected by
replicative senescence [25]. In the hepatocytes this latter can be the result of an enhanced
proliferation rate that can persist for 20-30 years of chronic liver disease. It is possible to
hypothesize that the parallel proliferative activity of progenitor cells and mesenchymal cells
allows an influence of the latter elements on the progenitor cells carcinogenic evolution: it is
known that sinusoidal lining cells like hepatic stellate cells proliferate in close anatomical
relationship with progenitor cells and are able to produce growth factors for which progenitor
cells have the receptors, suggesting an interaction between these cell compartments [26].
“A characteristic of stem cells is to survive to toxic and hypoxic stimuli due to their low cell
cycling “.
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“One possibility is that HLSC may represent a mesenchymal population modified by the
influence of the local environment, reflecting the importance of the niche in establishing the
phenotype of MSC” [42].
The “tumor stroma“ can be considered as “normal wound healing gone awry [43], able to
interact through paracrine and juxtacrine pathways with the tumor stem cells that are
influenced by the microenvironment in which they are endowed, with a direct role of micro‐
environment cells in determining the malignant phenotype [44-52]. In summary, fetal devel‐
opment, regeneration and carcinogenetic processes show some point of similarity in molecular
pathways and mechanisms, partly recapitulatedin chronic parenchymal liver damage evolv‐
ing to advanced stages.
Starting from the concept of chronic liver disease development, with progressive liver cell
destruction, reactive fibrosis and general parenchymal organization disarray, it is possible a
better comprehension of the whole changes.
These phenomena are all present since the beginning of liver damage, when liver cells are
involved by viral or toxic damage and fibrous tissue deposition replace the destroyed cells.
This is the beginning of fibrosis development, firstly at sub-sinusoidal level, then within the
damaged areas, often associated, in more advanced stages, with a ductular reaction.
Importantly, evolution of liver fibrosis and activation of hepatic stellate cells share some
pathways [4]. In fact, the adhesion molecules and receptors mediating cell-extracellular matrix
binding and growth factors and cytokines present in ECM influence matrix turnover and
modifications and, together with liver cells, endothelium, Kupffer cells and inflammatory cells,
modulate hepatic stellate cells. These latter express Integrins, mediating cell adhesion to
fibronectin and collagens and modulating metalloproteinases: integrins activate intracellular
signaling pathways in response to ECM protein they recognize, influencing hepatocytes
differentiation.
As a consequence, any kind of liver parenchymal damage, though mild, induces a regenerative
liver cell response, starting from periportal liver cells [25].
Liver cells, ductular cells, stromal cells and perisinusoidal cells all undergo regenerative
phenomena: it is a complex sequence associated with progressive collagen deposition with a
healing role, involving subsinusoidalDisse spaces, periportal and perilaminarinterstitium,
with ECM and parenchymal cells activation and proliferation and with ECM synthesis by
stellate cells, fibroblasts and, in some cases, parenchymal cells. In fact, in this context, epithelial-
mesenchymal transition and mesenchymal-epithelial transition play a role, with different
tissue component phenotypic changes, significantly involving parenchymal structure and
function [53].
If chronic inflammation with long standing tissue damage represents a risk condition for
neoplastic disease, cirrhosis is the typical predisposing setting for hepatocellular carcinoma.
In fact, cirrhosis is characterized by a microenvironment possibly favoring HCC onset: most
cases of hepatocellular carcinoma are linked to the presence of cirrhosis [54, 55].
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3. Molecular changes in the development of HCC: The novel role of miRNA
During the last years it has been shown a significant correspondence between clinical and
humoral parameters (tumor size, differentiation grading, HBV or HCV infection, serum
alfafeto protein (AFP)) and different molecular pathways activated in HCC cases: beta-catenin
and Axin-1 mutated cases, with early relapse, behave in a different way comparedto cases with
c-Myc and AKT activation associated with Interferon target genes inhibition, but also com‐
pared to hepatocellular carcinoma with overexpression of p53 and p21, the latter showing
better differentiation and lower size [56]. Subclasses S1,S2,S3 defined on the basis of above
mentioned clinical, humoraland morphological parametersare oftenassociated with different
molecular profiles: S1 show Beta catenin and Axin mutation; S2 activation of c-Myc, AFP
overexpression, AKT activation, IFN target genes inhibition; S3 cases are associated with better
histological differentiation, overexpression of p53, p21, gene related with glycolipidic and
alcohol metabolism, oxygen radical scavenging and coagulation [56]. The effort is the identi‐
fication of a classification system on the basis or with the contribution of the molecular changes
of the tumors.
At this regard, miRNAs can play a crucial role.  In fact,  each of these small  endogenous
non-coding RNAs is characterized by the ability to transcriptionally or post-transcriptional‐
ly  regulate  many  different  target  genes,  thus  being  responsible  of  complex  molecular
changes [57].
In fact, these sequences favor mRNA degradation through sequence-specific interaction with
the 3’ untranslated region (3’-UTR) of targeted mRNAs; when the sequence is totally comple‐
mentary, miRNA pairing will induce mRNA degradation and are involved in development,
apoptosis, proliferation and differentiation processes [58]. Alternatively, sequences partially
complementary will more probably induce a stop in translation, without mRNA degradation.
Therefore, a single miRNA is able to regulate the genic expression of hundreds of target
genes.Its altered expression could cause a “post transcriptional collapse”, i.e. the contemporary
deregulation of multiple tumor suppressor or oncogenes whose sequences are complementary
to the considered miRNA [59], thus deregulating many molecular pathways which could favor
a malignant cellular phenotype [57]. In fact, the global effect of inactivation of a miRNA
molecule will be the over-expression of its target genes, while its activation will induce the
down-regulation of a lot of target genes. If deregulated miRNA target genes are involved in
the regulation of important biological processes, such as apoptosis, cell cycle, tumoral cells
invasiveness or angiogenesis, then the risk of uncontrolled growth and tumor development
will increase [58].
Accordingly, in HCC has been described a deregulation of miRNA expression [57]. The fact
that HCC-related changes in miRNA expression are absent in non-neoplastic parenchyma and
the association of these changes with other neoplasms confirm the hypothesis of miRNA
involvement in HCC pathogenesis.
Interestingly, more than 50% of miRNA genes are located in fragile chromosomal site or in
cancer-associated genomic regions [60].
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Many experimental evidences support the relationship between fragile sites and DNA
instability in cancerous cells. In fact, fragile sites are preferential sites for chromatids exchang‐
es, translocations, deletions, gene amplification or integrations of associated viral sequences,
such as HPV [60].
Besides the association with fragile sites, microRNA genes may be involved in tumorigenesis
process through other mechanisms, such as point mutation, deletion, amplification, translo‐
cation or epigenetic modifications [61]. Most known microRNA have been identified within
genomic cancer-associated regions: minimal regions of loss of heterozigosity, where often
oncosuppressor genes are present or minimal region of amplification, where often oncogenes
have been identified [62]. This strongly suggest that miRNAgenes may behave either as
oncogenes or as tumor suppressor genes and, in particular, the same miRNA may behave in
different way on the basis of the kind of alteration, cellular type or transcriptional/post-
transcriptional regulation of target genes.
miRNA deregulation can also be the consequence of epigenetic changes, In fact, an extensive
genomic analysis of miRNA-coding gene sequences showed that about 50% of these loci are
CpG island associated [62] makingpossible that an alteration in DNA methylation/acethylation
could be responsible for miRNA deregulation in tumors [63].
Regarding the changes in miRNA expression in different tumors, the Volinia study [64],
performed a microarray analysis of 20 different miRNAs in 540 specimen obtained from
different tumor types (lung, breast, stomach, prostate, colon, pancreas) identifying a miRNA
signature common to some different solid tumors). The value of this study, find a confirma‐
tion in the similar grouping,  between different tumors,  of  the miRNA expression signa‐
ture: this suggest a common mechanism of involvement of miRNA in human carcinogenesis.
Prostate,  colon,  stomach,  pancreas  show mostly  similar  signature among them, whereas
lung and breast  are  represented by a  fairly  different  signature.  Furthermore,  within the
signature, some miRNA have been found whose association with other human tumors was
already known: among them there are miR-17-5p, miR-20a, miR-21, miR-92, miR-106a, e
miR-155, and molecular targets of these miRNA are significantly rich in tumor suppres‐
sor  genes  and oncogenes.  These data  suggest  the  crucial  involvement  of  miRNA in the
pathogenesis of solid tumors and confirm the function of miRNA as dominant and recessive
tumoral genes. Furthermore, it has been shown the role of miRNA not only in the early
phases of primitive tumors development, but also during the progression and the metastat‐
ic diffusion of the neoplastic disease. In fact, many experimental evidences show miRNA
involvement in the regulation of biological process leading to the acquisition of metastat‐
ic potential, such as adhesion, invasion, migration, epithelial-to-mesenchymal transition and
angiogenesis [65, 66].
Among miRNAs with an aberrant expression in both HCC and other solid tumors, we must
list: miR221/222 (up-regulated in HCC, colon, pancreas and gastric cancer); miR-21 (up-
regulated in HCC, ovarian, lung, breast cancer and glioblastoma); miR-199a, 200b and 214
(down-regulated in HCC and ovarian cancer) and miR-199b (down-regulated in HCC, ovarian
and lung cancer). Importantly, genes frequently de-regulated in HCC, such as p27/CDKN1B
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and p57/CDKN1C or PTEN, have been identified as targets of miR-221/222 and miR-21 targets
(see below).
Considering HCC-specific miRNAs, miR-122 is one of the best characterized molecules.
miR-122 is, in fact, a liver specific miRNA, representing 70% of all liver expressed miRNAs,
and it is down-regulated in most human and murine HCC. Its deregulation induces important
changes in the phenotype of adult hepatocytes and in several liver functions, such as lipid
metabolism [67] and cholesterol synthesis [68]. These data allow hypothesizing a correlation
between the lowered miR-122 expression in HCC and the loss of hepatic differentiation in
neoplastic cells. Furthermore, Joplinget alhave demonstrated that miR-122 is able to bind to 5’-
UTR RNA region of HCV [69]: this region is preserved in all six viral genotypes, so suggesting
that miR-122 is an essential element for virus replication in hepatocytes. It has been shown that
functional inactivation of miR-122 induces the 80% reduction of viral replication, suggesting
that miR-122 inactivation in hepatocellular carcinoma could increase neoplastic cells resistance
to HCV replication.
Concerning the miRNA involvement in different steps of hepatocellular carcinoma progres‐
sion, it has been demonstrated a correlation between miR-222, miR-106, miR-92, miR-17-5p,
miR-20, miR-18 and hepatocellular carcinoma differentiation grading, suggesting the involve‐
ment of a restricted number of miRNA in neoplastic progression [70]. According to this data
a 20 miRNAs signature has been reported [71], capable to distinguish primitive hepatocellular
carcinoma metastasizing through venous channels from solitary, non-metastatic tumors.
Furthermore, a predictive analysis revealed that most of 20 miRNA of HCC signature are
associated with patients’ survival. These signatures could then represent a simple method for
a diagnostic/prognostic profiling, capable of identifying HCC patients at high risk of devel‐
oping a metastatic disease or a liver relapse.
Other authors evaluate the predictive accuracy in distinguishing neoplastic and non-neoplastic
parenchyma equal to97,8% on the basis of 8 miRNAs, while others again identify 18 overex‐
pressed miRNA in hepatocellular carcinoma and only 6 overexpressedin non-neoplastic tissue
[72] (and with aberrant miR-21 expression associated with metastasis risk and connected with
PTEN targeting; miR-224 could act on genes apoptosis regulating (API-5) [73, 74].
Another miRNA involved in tumor progression and diffusion is miR-34a, a transcriptional
target of p53, deleted in many human neoplastic lesions. Besides molecular targets involved
in cell cycle progression, miR-34a regulates the expression of the oncoprotein c-Met, a tyrosin
kinase receptor activated by the hepatocyte growth factor binding, able to induce the phos‐
phorilation of molecules responsible for signal transduction, such as ERK1/2, thus exerting the
function of key factors in tumor invasion and migration regulation.
A recent study [66] reported a significant reduction of miR-34a expression in most carcinom‐
atous liver tissue with respect to non-neoplastic adjacent liver tissue, with an inverse correla‐
tion between miR-34a-and c-Met-expression levels. Furthermore, low levels of miR-34a
positively relate with the development of metastatic disease and neoplastic vascular invasion.
Accordingly, in vitro studies showed a lower migration and metastatic potential of neoplastic
cells after miR-34a c-Met dependent suppression.
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It is worth noting that another mi-RNA under-expressed in most HCC [75], miR-199a-3p, is
capable of regulating c-Met oncogene expression [76]:these data suggest that various deregu‐
lated miRNA in a specific neoplasia may modulate the same target gene, leading to strong
alteration of the molecular pathways downstream the target gene, thus influencing the tumor
progression.
RAS oncogene overexpression is associated to miRNA deregulation without oncogene point
mutation. Pathway alteration can be induced by downregulation of let-7 miRNA family
component.
Regarding the biological processes controlled by miRNAs, they play a direct role on cellular
growth control. As previously mentioned, miR-221 is up-regulated in many neoplasms and
influence the expression of the cyclin-dependent kinase inhibitor CDKN1B/p27, which
controls the cell cycle progression [57]. The activation of pathways involving PI3K/AKT leads
to phosphorylation of proteins that favor cell survival, under the control of tumor suppressor
lipid phosphatase PTEN, which is a direct miR-21 target; in vitro studies showed the associa‐
tion between mir-21 inhibition and PTEN overexpression, with subsequent decreased neo‐
plastic cell proliferation and invasion [57]. Moreover, MiR-21 inhibition induces changes in
metalloproteinases 2 and 9 expression: both these molecules are downstream PTEN mediators
with a known role in cellular migration and invasion [57]. These data suggest that the aberrant
miR-21 expression may favor HCC growth and diffusion through the modulation of the
expression of PTEN and of PTEN-dependent pathways involved in neoplastic cells phenotype
and behavior modulation. Again, cyclin G1 upregulation following miR-122 down-regulation
may induce p53 down-regulation, so favoring tumorigenesis [57].
Regarding the role of miRNA as biomarkers, there is evidence that, in HCC, miRNAs could
have a prognostic as well as a diagnostic role.
As already underlined, some known molecular factors characterizing HCC may play a role as
prognostic factors (for example c-MET or p27); similarly, there is evidence that some deregu‐
lated miR [58] may allow, in association with clinical parameters and histological patterns,
classifying HCC, thus identifying new criteria for prognostic stratification [57]. This is also
possible due to distinct miRNA profiles of different hepatocellular carcinoma subtypes (at
variance with similar signature between tumors in different organs)Such a differentiation takes
place on the basis of supposed mechanism of origin (cancer stem cells or mature hepatocyte-
like): the different groups show distinctbiological behavior. Furthermore,HBV or HCV
etiology of basic disease and primary or metastatic nature of the neoplastic lesion are associated
with different miRNA signatures in HCC [60].
Regarding the potential role of miRNAs as diagnostic biomarkers, at least 20 miRNAs show
different changes between lesions with different origin; cancer stem cells origin is associated
with self-renewal capability, differentiation and aggressive tumorigenesis in vivo: miR-181
family members, over-expressed in HCC, favor the origin of neoplasia from progenitor cells
through an influence on CDX2 and GATA6, differentiation related genes, and on NLK a WNT/
Beta catenin pathway inhibitor.
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MiR-21, miR-10b, miR-222 and miR-224 are highly represented in HCC, while non-malignant
hepatic lesions show decreased miR-202 and miR-203 expression. Alcohol consumption
related hepatocellular carcinoma shows low miR-126 levels, while high levels of miR-96 are
present in neoplastic lesions HBV associated: such alterations have not been shown in non-
neoplastic parenchyma [58]. Furthermore, hepatocellular carcinoma cases with high risk of
metastatic diffusion and cases without metastasis risk present distinct miRNA groups’
expression.
Low miR-375 expression have been shown either in hepatocellular adenoma or in carcinoma
with Beta catenin mutation: the significant inverse correlation between miR-375 level and Beta
catenin targeted gene expression suggests a direct relationship between Beta catenin activation
and miR-375 repression [58]. Recently a role of survival predictor and IFN adjuvant therapy
response in hepatocellular carcinoma for miR-26 has been identified [77].
Finally, as previously mentioned, genetic mutations and transcriptional, epigenetic changes
may induce miRNA alterations. In the case of HCC it has been shown the role of endoribonu‐
clease III DICER for miRNA maturation: its role in cleavage and maturation of miRNA renders
impossible for the cell a full expression of miRNA if endoribonuclease is disrupted. DICER
deficient hepatocytes loose the expression of all miRNA, with expression of liver specific fetal
genes and deregulation of much genes related to neoplastic development [60].
In  conclusion,  up  to  date  experimental  evidences  show  that  hepatocellular  carcinoma
subtypes  are  characterized  by  distinct  miRNA  expression  profiles,  related  to  grade  of
aggressiveness, risk factors and genetic changes. MiRNAs may therefore represent not only
useful  diagnostic  and  prognostic  markers,  but  important  target  molecules  for  potential
therapeutic treatment.
4. Tumor associated fibroblast in the development of HCC
If molecular changes take place in liver parenchymal cells undergoing to inflammatory and
fibrotic parenchymal damage, leading to the phenomena that characterize tumoral initiation
and progression, then, it is also an important matter the evaluation of the role of inflammatory
conditions and fibrosis in stromal changes, and, particularly, in tumor associated fibroblasts
development.
Among the constituents of the tumor microenvironment, tumor associated fibroblasts (TAF)
play a key role in tumor progression, angiogenesis, growth and metastasis: they are charac‐
terized by the expression of specific markers [45, 78-82] and seems to assume a role in clinical
tumor prognosis.
Recently [83, 84] it has been optimized a method to isolate, from several human adult tissues,
a population of primitive cells, named multipotent adult stem cells (MASCs) with mesenchy‐
malimmunophenotype, clonogenicity and multiple in vitro differentiation capacity [83, 84].
MASCs isolated both from neoplastic and from cirrhotic human liver tissue allow to test the
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hypothesis that liver resident MASCs could generate TAFs in pathological conditions: a
population of MASCs with TAFs characteristics both in human hepatocellular carcinoma and
cirrhotic liver has been demonstrated, so suggesting a possible role in the development of
neoplasia in the adequate environment [2]. On the other hand, TAFs from non-neoplastic and
non-cirrhotic livers do not show aberrant growth properties: so, TAFs can originate from
resident primitive cells [2].
The in vivo counterpart of MASCs is still undefined, but the interesting data concern their
sharing of some feature with activated hepatic stellate cells [85-87]. This aspect is of particular
interest, given the hypothesis that stellate cells could be progenitor cells: in fact, the expression
of OCT-4 and of markers of all the three germ layers and their ability to give rise in vitro to
endothelial cells and hepatocytes offer essential elements [2].
A fate-mapping study showed that stellate cells could become oval cells when activated in
liver injury, and that these cells participate in ductular proliferation [88]. This offers a sub‐
stantial contribution to the discussed sharing of pathways and cells between developmental,
regenerative and neoplastic processes in the liver.
All these evidences point to the presence of mesenchymal, widely multipotent cells in adult
tissues, which can take partto regenerative as well as inflammatory and neoplastic processes [89].
In the paper by Cesselli et al 2011 [2] it is well documented that MASCs isolated from hepa‐
tocellular carcinoma have the main characteristic of TAFs, at variance with cells from non-
neoplastic and non-cirrhotic livers. TAFs act on the tumor growth in different ways, which are
able to modify the microenvironment in the sense of a more suitable situation for the increase
of tumor growth [48, 78, 90]. TAFs are contractile cells, with a strict spatial relation with blood
vessels; they produce growth factors (HGF, TGF beta, EGF, bFGF, IGF), cytokines, chemokines,
enzymes; they can degrade the extracellular matrix and can behave as immunomodulating
cells [48, 78, 90]. Finally, increased metastatic potential and poor prognosis are associated with
the presence of TAFs [48].
Tumor cell lines medium can induce in L-MASCs aberrant growth properties and the ability
to produce specific TAF markers [47, 48, 78]. The origin of TAFs seems to be connected with
four possible sources: epithelial-mesenchymal transition of the neoplastic cells (associated
with genetic changes within the TAFs); recruitment and activation of resident fibroblasts;
recruitment of circulating/bone marrow derived mesenchymal stem cells; recruitment of
mesenchymal stem cells [48, 78, 82]. In the paper from Cesselli, Beltrami et al. it has been shown
the origin of TAFs from a population of resident primitive cells with mesenchymal features
[2].The Authors also underline that blocking the activation of TAFs and their continuous
communication with the cancer cells could, in conjunction with chemotherapy regimens, limit
tumor progression and metastasis [45, 82, 91]: the much lower instability of TAFs versus
malignant cells seems to make them less likely to undergo the onset of resistance to chemo‐
therapy drugs [81, 92].
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5. Conclusions
Liver parenchyma, exposed to long standing viral or toxic damage, undergoes a diffuse,
fibrosing rearrangement, developing cirrhosis. In this context, genetic changes in the cellular
component, the activation of different pathways, the production of cytokines and growth
factors, phenotypic changes of epithelial or mesenchymal cells produce complex phenomena,
involving regenerative, preneoplastic and neoplastic changes.The role of liver cells and/or
progenitor cells in neoplastic growth is heavily influenced by mesenchymal component, in
particular by TAFs. Cirrhotic livers, when not yet neoplastic, already possess a population of
multipotent adult stem cells with TAFs properties.
The possible origin of TAFs from a population of primitive mesenchymal stem cells gives to
the tumor supporting stroma a more complex and important role. In fact, from “ rare resident
stem cells, such as multipotent adult stem cells (MASCs) “ the entire formation and instruction
of the elements of supportive microenvironment could take place [2]. MASCs differentiation
potential “ into many stromal cell types and their molecular signature consisting of overex‐
pression “ of a gene panel involved in extracellular matrix remodeling, immunomodulation,
and cytokines and growth factors production [83] offer a key to understand the relationship
between liver parenchyma, neoplastic growth and stromal component.
“ Multipotent adult stem cells isolated from healthy livers can acquire a TAF phenotype when
grown in conditional medium from tumor cell lines, suggesting that multipotent cells residing
in the liver may represent a population “ able to stroma formation and contributing to tumor
progression, in adequate conditions [2]. The effort to identify novel therapies aimed at
interfering with the interaction between stroma and cancer cells represent a crucial perspective.
The discovery, in 1993, by Ambros and Ruvkun of this new mechanism of gene regulation,
with large mRNA under the control of a small RNA opened a new way to develop the
understanding of the regulation of critical cellular process (cell division, metabolism, devel‐
opment and death) by micro RNA. MiRNA can target more than 500 mRNA and a single
mRNA can be targeted by multiple miRNA. The specificity of targets depend on the degree
of base complementarities to the target mRNA: when the miRNA have perfect base comple‐
mentarities, than messenger RNA undergo degradation; if there is not perfect complementar‐
ity, than posttranslational inhibition occur. Through this mechanism, miRNA can exert an
essential control on a lot of processes, in particular in neoplasia harboring and diffusion,
opening a crucial field in prognostic prediction and in possible intervention to break the
carcinogenetic process and to obtain the disease control through target therapy.
The concepts of multidirectional differentiation of mesenchymal stem cells, of tumor associ‐
ated fibroblasts, of cancerization fields, epithelial-mesenchymal transition and mesenchymal-
epithelial transition, miRNA deregulation,the progress in the identification of reproducible
classification criteria on the basis of hepatocellular carcinomamolecular changes offer new
insights concerning liver neoplastic growths, with key points concerning the association
between developmental, regenerative and neoplastic growth mechanisms and the relationship
between parenchymal hepatocytes and stromal component in preneoplastic and neoplastic
liver diseases as the main ways for a better understanding of neoplastic liver biology.
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